Alkermes results, outlook

 —    Total Revenues of $1.56 Billion in 2024; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year —

—    GAAP Net Income from Continuing Operations of $372 Million and Diluted GAAP Earnings per Share from Continuing Operations of $2.20 for 2024 —

—    ALKS 2680 Phase 2 Studies in Narcolepsy Type 1 and Type 2 Ongoing With Data Expected in H2 2025 —

Financial Expectations for 2025

All line items are according to GAAP, except as otherwise noted.

In millions		2025 Expectations
Total Revenues		$1,340 – $1,430
VIVITROL Net Sales		$440 – $460
ARISTADAi Net Sales		$335 – $355
LYBALVI Net Sales		$320 – $340
Cost of Goods Sold		$185 – $205
R&D Expenses		$305 – $335
SG&A Expenses		$655 – $685
GAAP Net Income a		$175 – $205
EBITDA		$215 – $245
Adjusted EBITDA		$310 – $340
Effective Tax Rate		~17%

a Expected 2025 weighted average basic share count of approximately 165.5 million shares outstanding and a weighted average diluted share count of approximately 169.5 million shares outstanding.

Conference Call

Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. EST (1:00 p.m. GMT) on Wednesday, Feb. 12, 2025, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.

https://www.prnewswire.co.uk/news-releases/alkermes-plc-reports-financial-results-for-the-fourth-quarter-and-year-ended-dec-31-2024-and-provides-financial-expectations-for-2025-302373974.html